Canature announced in the morning of Dec. 21, Origincell Technology Group, its holding subsidiary signed a strategic cooperative agreement with NextCODE on Dec. 17 to build a cooperative mechanism on sequencing detection, immune anti-aging, cells therapy and its related pharmaceutical research.

NextCODE is the subsidiary of Wuxi Pharma Tech which was established in Dec., 2000, a global leader of open ability and technological platform company in pharmacy, biotech and medical equipment R&D. NextCODE possesses international cutting-edge integrated ability in genetic medicine embracing the comprehensive sequencing ability based on CLIA IQ lab, leading gene sequencing analyzing system, new developed database frame which can realize speedy and effective large-scaled genetic data searching, managing, storing and sharing to applying to the professional knowledge and experience for genomics all-round optimized pharmacy development.

Origincell Group was founded by Canature and Mr. Qu Jianguo, a famous entrepreneur in Shanghai with ￥500 million registered capital devoting itself into large-scaled international and professional automated auto cells storage and relevant technology, R&D, utilizing, transforming, the “big health industry”, etc.